33.9 C
Vientiane
Monday, June 2, 2025
spot_img
Home Blog Page 468

DB HiTek to Participate in PCIM 2025, Strengthening Marketing in Europe

Germany’s Largest Power Semiconductor Exhibition in Nuremberg (May 6–8)
… Sharing the latest developments in Analog & Power, Specialty CIS, SiC and GaN technologies 

SEOUL, South Korea, April 7, 2025 /PRNewswire/ — DB HiTek, a leading 8-inch foundry company, will participate in PCIM 2025, Europe’s largest power semiconductor exhibition, held in Nuremberg, Germany, from May 6 to May 8 (local time), to expand its presence in the European market.

At the exhibition, DB HiTek plans to showcase the latest technology developments in its world-best BCDMOS, Specialty CIS, and the next-generation power semiconductor SiC and GaN. Notably, the company’s SiC and GaN power semiconductor processes, which DB HiTek has been actively developing as key future growth drivers, will be prominently featured at the event.

In February, DB HiTek secured the basic characteristics of its 8-inch SiC wafer through full in-house processing. The company aims to improve yield and reliability throughout this year and plans to offer the process to its customers by late 2025.

Additionally, DB HiTek has successfully developed an 8-inch GaN process with 650V HEMT characteristics and plans to complete reliability validation within the year. The company announced that it will launch a dedicated GaN MPW service in October, actively supporting customer product evaluations.

According to market research firm Yole Développement, the global SiC and GaN power semiconductor market is expected to grow from $3.6 billion in 2024 to $7.6 billion in 2027, with a high CAGR of 27.6%.

Regarding its participation in PCIM 2025, DB HiTek commented, “This exhibition will provide an opportunity to demonstrate our recognized strengths in supporting fabless customers and collaborating with global clients in the European market.”

DB HiTek has established itself as a global leader in 8-inch Analog and Power semiconductor processes. However, the European customer base remains relatively small compared to other regions. The company aims to use this event to expand its footprint in the growing European market by acquiring new customers and strengthening collaborations with existing clients.

Currently, DB HiTek is mass-producing chips for 400 companies, with cumulative shipments of 6 million 8-inch wafers for Analog and Power semiconductor. The company has also secured Specialty CIS process technologies, including X-ray sensors, Global Shutter, and SPAD, and is actively engaged in mass production with various partners. Its semiconductor applications span mobile, consumer, and industrial sectors, with a growing share of automotive chips in recent years.

CIBF2025 to Unveil Breakthroughs Shaping the Future of Energy Storage

Batteries Spearhead Dual Economic and Technological Race in 2025 

TIANJIN, China, April 7, 2025 /PRNewswire/ — The 17th China International Battery Fair (CIBF2025), Asia’s premier battery industry gathering, will be held at the Shenzhen Convention & Exhibition Center from May 15-17, 2025. Organized by the China Industrial Association of Power Sources (CIAPS), the 300,000-sqm event will span 15 halls, hosting 3,100 global exhibitors spotlighting next-gen technologies and solutions. 

Pavilion Floor Plan
Pavilion Floor Plan

Industry Giants to Showcase Synergies Between Innovation and Commercialization

Confirmed participants include industry leaders CATL, BYD, EVE Energy, Gotion High-tech, Cornex, Sunwoda, and Lishen Battery, alongside Dynanonic, Hunan Yuneng, SEMCORP and other key suppliers. The event will also highlight advancements in smart battery management systems (BMS) and energy storage solutions. In a move to streamline event access, CIBF2025 has set up two registration entrances (North/South), in anticipation of the more than 400,000 professional buyers and visitors worldwide, who are looking forward to the opportunities for networking and deal-making. 

CIBF exhibit
CIBF exhibit

Attendees to the CIBF2025 Conference on the Frontier Technology of Advanced Batteries taking place concurrently will discuss critical industry themes of the day, with a focus on the lastest advancements in lithium-ion batteries, battery safety and testing, solid-state and next-gen batteries, high-power fast charging, sodium-ion batteries, advanced materials, and smart manufacturing with digital twins

Additionally, the event will host several high-level forums including the Electric Aviation & Next-Gen Batteries (CIBF2025 Shenzhen) Technical Conference, the CIBICS Battery Industry Cooperation Forum, and the Isotope Nuclear Battery Status and Future Development Symposium, in addition to more than 200 technical presentations to decode emerging trends and explore the future of battery ecosystems.

CIBF2023 conference on-site
CIBF2023 conference on-site

The TWh Era Arrives: Batteries Power Economic Growth

China’s lithium battery industry achieved landmark growth in 2024, with total output surging 24% year on year to 1,170GWh and industry valuation exceeding 1.2 trillion yuan. The sector demonstrated balanced growth across key applications: consumer electronics (84GWh); energy storage (260GWh); and power batteries (826GWh). Total installations surpassed 645GWh, reflecting a year-on-year increase of 48%. 

CIBF Exhibition Hall
CIBF Exhibition Hall

Electric vehicles (EVs) have cemented China’s leadership in the global battery revolution. With 2024 power battery shipments rising to 1,157GWh worldwide, the industry has decisively crossed into the TWh era – a milestone underscored by Chinese firms’ growing market dominance.

The lithium battery boom extends beyond EVs, with energy storage deployments reaching record highs. According to BloombergNEF and SNE Research, global installations for energy storage exceeded 175GWh in 2024, while shipments surged 64% year-on-year to 303GWh. Chinese battery manufacturers are emerging as key drivers of the global clean energy transition.

The low-altitude economy has evolved into a strategic growth sector, featured prominently in regional government blueprints and poised to unlock a new trillion-yuan market. Over 10 innovative applications—among them, air taxis, emergency rescue systems, drone logistics, and regional air mobility—are creating unprecedented demand for advanced battery solutions. 

As new entrants flood this high-potential market, competition is accelerating breakthroughs in critical technologies, including enhanced safety protocols, ultra-fast charging capabilities, high energy density solutions, and extended cycle life performance.

Join the event at CIBF2025, May 15-17, 2025, at the Shenzhen Convention & Exhibition Center.

CIBF2025
CIBF2025

 

TDCX acquires Open Access BPO to capitalize on global shift towards strategic outsourcing

  • Adds delivery locations in Davao, Manila and Taipei
  • Eyes opportunities to support foundation model and autonomous vehicle companies
SINGAPORE – Media OutReach Newswire – 7 April 2025 – TDCX, an award-winning digital customer experience (CX) solutions provider for technology and blue-chip companies, today announced its acquisition of Open Access BPO, a United States (US) headquartered outsourcing company. The acquisition strengthens TDCX’s ability to meet the growing demand for strategic outsourced services, with new locations in Davao, Manila and Taipei, as companies seek to leverage outsourcing to cope with the fast-changing business environment and tight labor market.

The global business process outsourcing (BPO) market is expected to hit US$491.53 billion by 2029, with Asia alone growing at a compounded annual growth rate of 5.9 per cent to become a US$109.92 billion industry by 2029[1]. The ability for BPO partners to deliver intelligent solutions with better insights and problem-solving for more complex issues makes it an attractive option for companies, increasing their agility and freeing them up to focus on core competitive business activities.

Mr. Laurent Junique, CEO and Founder, TDCX, said, “Business cycles are moving more quickly than ever. Strategic outsourcing is similarly evolving at a rapid pace. Companies at the forefront of leveraging strategic outsourcing see it as a critical driver for innovation, flexibility, and global expansion and our acquisition of Open Access BPO strengthens our ability to seize these opportunities. With our combined delivery locations and deepened expertise in verticals including fintech and healthtech, we will be able to create greater value for our colleagues and clients.

“This milestone is another step in our ambition to support the growth of the digital economy. Over the last two decades, we have been a key partner to many ‘born-digital’ companies as they scaled their operations. We now see a new wave of innovators and industries such as foundation model companies building artificial intelligence that can reason and generate human-like text, autonomous vehicle firms revolutionizing transportation and humanoid robotics companies creating intelligent machines for labor and logistics. Many of these barely existed a decade ago and we see great potential in supporting companies that are now shaping the future of technology and business.”

Mr. Ben Davidowitz, CEO, Open Access BPO, said, “The outsourced CX industry is poised for growth, driven by the increasing demand for personalized customer experiences and adoption of advanced technologies. By joining forces with TDCX, we open more options for our clients and have greater scale to compete on the global stage. Our employees will similarly benefit from the combined organization, given the strong cultural alignment and common desire to provide fulfilling careers for our people. I would like to take the opportunity to thank our employees for their outstanding work and dedication to our valued clients. Looking ahead, we are eager to leverage our strengths and further our passion for delivering exceptional CX.”

Both companies will continue to operate under their respective brands to ensure a seamless transition for employees, clients, and partners. Open Access BPO’s leadership, specifically Mr. Davidowitz, CEO, and Mr. Henry Chang, President and co-founder, will continue to serve as advisors. Joy Sebastian, Vice President of Global Operations at Open Access BPO, along with the rest of the leadership team, will continue to play a key role in managing operations to ensure a smooth transition for clients.

Baird acted as financial advisor to Open Access BPO, with Reed Smith LLP as its legal counsel. Clark Hill PLC served as legal advisor to TDCX.


[1] Source: Business Process Outsourcing: market data & analysis, Statista Market Insights 2024.

Hashtag: #TDCX


The issuer is solely responsible for the content of this announcement.

About TDCX

Singapore-based TDCX is a global business process outsourcing (BPO) leader, offering advanced customer experience (CX) solutions, sales and digital marketing services, and content moderation. It caters to industries like digital advertising, social media, e-commerce, fintech, gaming, healthtech, media, tech, and travel & hospitality.

TDCX’s smart, scalable approach—driven by innovation and operational precision—positions it as a key partner for companies targeting tangible outcomes.

With more than 20,000 employees spanning 39 locations worldwide, TDCX delivers robust coverage across Asia, Europe, and the U.S. Check out for more info.

About Open Access BPO

Founded in 2006, Open Access BPO is a high-growth provider of omnichannel and multilingual client experience, back-office support and content moderation solutions, providing end-to-end business operations support to global blue-chip companies in the healthcare, technology, financial services, e-commerce, and human capital management industries.

Open Access BPO’s solutions aim to help global brands manage their clients’ needs while enriching consumer experiences across multiple touch points and channels.

Open Access BPO leverages an effective Asia-based offshore delivery model with cost-efficient and scalable operations in the Philippines and Taiwan.

ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases

– ABL Bio and GSK enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases

– Programs will leverage ABL Bio’s Grabody-B platform technology to effectively deliver molecules across the blood-brain barrier

– ABL Bio to receive up to £77 million in upfront and near-term payments 

SEONGNAM, South Korea, April 7, 2025 /PRNewswire/ — ABL Bio Inc. (KOSDAQ: 298380), a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, announced a worldwide licensing agreement enabling GSK to develop novel medicines for neurodegenerative diseases by utilizing ABL Bio’s blood-brain barrier (BBB) shuttle platform, Grabody-B. The agreement aims to develop multiple programs for novel targets across therapeutic modalities including antibody, polynucleotide or oligonucleotides, such as siRNA and ASOs, to address significant unmet medical needs of patients suffering from neurodegenerative conditions.

The blood-brain barrier (BBB) serves as a protective barrier that restricts the entry of harmful substances and agents into the brain and is considered a significant obstacle in the development of treatments for neurological diseases. ABL Bio’s Grabody-B was developed to overcome the limitations of existing drugs that have difficulty crossing the BBB by targeting the Insulin-like Growth Factor 1 Receptor (IGF1R), facilitating drug penetration across the BBB and enabling efficient delivery into the brain.

Under the terms of the agreement, ABL Bio will receive up to £77.1 million in upfront and near-term payments, including an immediate upfront payment of £38.5 million, research milestones and potential program expansion. In total, ABL Bio is eligible to receive up to £2.075 billion in research, development, regulatory and commercialization milestone payments across multiple potential programs. ABL Bio will receive tiered royalties on net sales if products are successfully commercialized. As part of the agreement, ABL Bio will transfer Grabody-B-related technology and know-how to GSK, while GSK will assume responsibility for preclinical and clinical development, manufacturing, and commercialization.

Christopher Austin, SVP of Research Technologies, GSK, said “There is a critical need for new therapeutics to treat neurodegenerative brain diseases, which are rapidly increasing in prevalence due to the aging of the population. Many of the most promising new therapies are antibodies, which cannot efficiently reach the brain without a shuttle to get them across the BBB. This agreement reflects our commitment to innovative platform technologies to overcome the BBB and thus open entirely new opportunities for treating these devastating diseases, an important component of our emerging pipeline.”

Sang Hoon Lee, CEO of ABL Bio said “This agreement underscores ABL Bio’s leadership in BBB technology and its commitment to advancing transformative therapeutics in neurodegenerative diseases through strategic partnership with global pharmaceutical leaders like GSK. Additionally, this agreement will serve as a great opportunity to strengthen ABL Bio’s position in the neurodegenerative disease treatment market through the potential commercialization of Grabody-B and to expand the modality areas where Grabody-B can be utilized. Given the increasing number of patients suffering from neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases, we hope this partnership will accelerate the development of innovative treatments and bring renewed hope to patients worldwide.”

About ABL Bio

ABL Bio is developing various clinical and non-clinical assets based on its bispecific antibody platform ‘Grabody’. Clinical projects for 7 pipelines, including ABL301, ABL001 (tovecimig), ABL111 (givastomig), ABL503 (ragistomig), ABL105, ABL202, and ABL103, are underway for different indications in various countries, including the United States, China, Australia, and Korea. In case of ABL001 (tovecimig), has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) to support the rapid development of this new drug candidate. In addition, ABL111 (givastomig), co-developed with I-Mab, is expected to disclose the top-line data from the Phase 1b clinical trial in 2025, evaluating the triple combination therapy with nivolumab and chemotherapy. Meanwhile, ABL Bio is preparing to initiate clinical trials for ABL104. In addition, ABL Bio is continuously researching and developing several other product candidates, including bispecific antibody-drug conjugates (ADCs).

Saramonic K9 Unveiled – Digital UHF Audio System With User Experience Friendlier for Filmmakers

NEW YORK, April 7, 2025 /PRNewswire/ — Saramonic launches Saramonic K9, its first dual-channel digital UHF wireless audio system for filmmakers during NAB Show 2025. This new system features what a professional looks for in a reliable audio system: ultra-wide 550-960 MHz digital UHF, 130 dB high dynamic range, 32-bit float onboard recording*, and timecode, giving filmmakers a friendlier user experience.

A Closer Look of Saramonic K9
A Closer Look of Saramonic K9

Cinema-Grade Precision And Reliability Redefined

Strong anti-interference performance, high-fidelity audio recordings, and safety backup constitute a reliable audio system. Designed with that in mind, Saramonic K9 is a digital UHF system that converts audio signals into a digital format before transmission, making it less prone to interference than analog. In addition, the ultra-wide UHF spectrum (550-960 MHz) it operates in offers more channels to auto-scan and locks onto optimal channels within 0.3 seconds, even in densely crowded RF environments.

The Saramonic K9 delivers cinematic clarity through its 130dB input – 120dB output dynamic range , capturing whispers to explosions without distortion. Engineered with industry-standard 32-bit float recording, Saramonic K9 preserves 192kHz/32bit fidelity across its full dynamic spectrum. Editors gain post-production superpowers: rescuing clipped dialogue, amplifying subtle ambiance, or isolating frequencies – all while maintaining phase accuracy.

Cinema-Ready Innovation for All Productions

  • 32-Bit Float Onboard Recording with 32GB storage safeguards pristine audio for post-production freedom, capturing whispers to explosions without clipping.
  • Timecode Sync ensures frame-perfect alignment across multi-camera shoots, slashing editing time.
  • Saramonic System controls up to 48 devices remotely, offering more flexibility when transmitters are hard to access.
  • Industry’s Smallest IP67 Lavalier Mic (Ø3mm) withstands dust, sweat, and rain while remaining virtually invisible on talent.
  • Dual-Screen Monitoring displays real-time transmitter status and RF health at a glance.

Availability

Saramonic K9 is available through Saramonic Online Store and worldwide dealers with a recommended retail price at EUR 999 (global version) and USD 999.99 (US version). Order now: saramonic.com/product/saramonic-k9-uhf-microphone

About Saramonic

Saramonic is a leading audio brand dedicated to empowering creators to sound remarkable. Founded in 2012, the company has built a strong foundation for innovation, which is supported by an R&D team of over 100 members, 400+ patents, and 5 acoustic labs. Today, Saramonic continues to drive innovation for its growing community of 40 million users.

Contact: Jingyi Chen, chenjinyi@sz-cf.cn

Agoda Highlights Top Markets Traveling to Thailand for Songkran 2025

SINGAPORE, April 7, 2025 /PRNewswire/ — Digital travel platform Agoda reveals the top international markets exploring traveling to Thailand for Songkran this year, with Malaysia leading the list. Based on accommodation searches made on Agoda, Malaysian travelers are followed by visitors from Hong Kong SAR, Indonesia, South Korea, and the Philippines when it comes to their eagerness to take part in the Thai New Year celebrations.

Songkran, celebrated annually from April 13-15, is famous for its spectacular water fights that take place across Thailand. The top five city destinations for international Songkran visitors are Bangkok, Pattaya, Phuket, Hat Yai, and Chiang Mai.

Key events in Bangkok include the Maha Songkran World Water Festival 2025, hosted by the Tourism Authority of Thailand (TAT), and the Siam Songkran Music Festival, featuring performances by renowned artists from around the globe.

Akaporn Rodkong, Country Director Thailand at Agoda, shared, “As the Songkran festival approaches, it’s exciting to see a wide range of international tourists considering visiting Thailand. And rightly so—Thailand’s lively celebrations and unique experiences create an atmosphere that’s hard to resist. Whether celebrating Songkran in Bangkok or exploring other destinations in Thailand, Agoda is here to help travelers find the best deals on flights, accommodations, and activities to make this festive season unforgettable.”

To make Songkran even more exciting and affordable, Agoda is offering a “Songkran Fest” promotion, providing travelers with up to 10% additional discounts at participating hotels in Thailand. The promotion is available for bookings and stays made before April 15, 2025. For more information, visit https://www.agoda.com/SongkranFestTH.

Hurom Wins Patent Infringement Case Against NUC (Kuvings) in European Unified Patent Court

Court Bans NUC Juicer Sales in Europe, Orders Compensation, Recall, and Destruction of Infringing Products

SEOUL, South Korea, April 7, 2025 /PRNewswire/ — Hurom, the global pioneer in slow juicing and the inventor of the world’s first vertical juicer, has secured a major legal victory against NUC, maker of the Kuvings juicer line, in the Unified Patent Court (UPC) of Europe.

On March 11, the UPC’s regional division in Mannheim, Germany ruled that NUC—including its Korean headquarters, European subsidiary, and distributor Warmcook—had infringed Hurom’s European patent (EP2028981).

As a result, NUC is now banned from selling its juicers in Europe, with any violations subject to a fine of €2,000 per infringing unit sold.

The court also ordered NUC to compensate Hurom for damages and cover all litigation costs, as well as recall and destroy all infringing products already distributed in the market. One of the key products found to be in violation is the Kuvings AUTO10 juicer.

This ruling follows Hurom’s previous legal wins in South Korea and the United States, further reinforcing its position as the original innovator behind vertical juicing technology.

In December 2024, the Korea Trade Commission determined that NUC had infringed Hurom’s patents and engaged in unfair trade practices, issuing a corrective order and imposing a fine. Similarly, in July 2024, Amazon’s Amazon Patent Evaluation Express (APEX) process (APEX ID: 15060613361) confirmed NUC’s patent infringement, resulting in the suspension of several key Kuvings juicer models in the U.S. market.  

Hurom CEO Jaewon Kim commented, “This ruling is a strong affirmation of Hurom’s technological leadership on the global stage,” and added, “We will continue to take firm action against reckless patent infringement and low-cost knockoffs that compromise our mission of promoting health through fruit and vegetable consumption.”

*Unified Patent Court (Germany) Case Numbers: PR_ACT_17336/2024, PR_ACT_17365/2024

George Clinical Rebrands as Emerald Clinical Trials

New name reflects company’s growth and vision to help bring certainty and transparency to global clinical trials

SINGAPORE, April 7, 2025 /PRNewswire/ — George Clinical, a leading clinical research organization (CRO) operating worldwide, is pleased to announce it has rebranded to become Emerald Clinical Trials. This strategic name change underscores the company’s well-established position as a dedicated, reliable, consistent, and flexible CRO, while mitigating global clinical development risks through deep therapeutic and local expertise cultivated over 20 years.

Emerald Clinical Trials continues to focus on end-to-end services across all therapeutic areas designed to change lives⁠ while ⁠advancing innovations that help evolve global clinical research practices. With its strong track record in Oncology and Cardio-Renal-Metabolic (CRM) therapeutic areas, trusted expertise in Asia Pacific, and global scientific leadership, Emerald Clinical Trials is a highly differentiated clinical CRO on the world stage. The company’s extensive reach operating directly in 42 countries and in 70 countries through partnerships ensures seamless execution of clinical trials worldwide.

The new brand amplifies the exceptional work of Emerald Clinical Trials and highlights the breadth and depth of its experience to an even broader audience. It emphasizes a strong commitment to patients, customers, and partners.

The company’s deep commitment to customer-centricity fosters long-term relationships built on trust, reliability, and measurable success. Emerald’s ability to deliver predictability in clinical trials is underscored by a track record of repeat business, industry excellence awards, and consistent performance in bringing therapies to market.

“For the past two decades, Emerald Clinical Trials has been focused on delivering high quality trials that combine a global reach with a high-touch approach. We offer the footprint and expertise of a large CRO with the personalized attention and flexibility of a smaller partner, ensuring that every client, from emerging biotech to top-tier pharma, receives the focused, hands-on support they need to de-risk their clinical programs,” said Mary Gunn, CEO, Emerald Clinical Trials. “This exciting transformation strengthens our position as a trusted partner in clinical trials, while reaffirming our commitment to our clients and core values.”

“We decided early on that we wanted to work with a CRO that has a flexible approach, and solutions tailored to the specific needs of each trial, whether accelerating timelines, adapting to evolving study requirements, or scaling resources efficiently,” said Dr. Daniel Tillett, CEO, Race Oncology, an Emerald client. “Agility is critical for biopharma companies that require a partner who can pivot alongside them, rather than slow them down with bureaucratic inefficiencies, and that is truly a strength of Emerald Clinical Trials.”

About Emerald Clinical Trials
Emerald Clinical Trials is a leading clinical research organization operating worldwide that serves over 100 biotechs, and 6 of the top 10 pharmaceutical companies. Headquartered in Singapore and driven by operational expertise and scientific excellence, the company provides comprehensive clinical trial services to clients globally, offering solutions across all trial phases. For more information, visit www.emeraldclinical.com.

Media Contact: Shannon Severino, shannon@severinocommunications.com, T +1 412 608 2393